Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

06:34
10/06/16
10/06
06:34
10/06/16
06:34

Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital

  • 07

    Oct

IONS Ionis Pharmaceuticals
$36.38

0.72 (2.02%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.

TODAY'S FREE FLY STORIES

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:32
02/23/17
02/23
06:32
02/23/17
06:32
Hot Stocks
Breaking Hot Stocks news story on SAGE Therapeutics »

SAGE Therapeutics sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Earnings
Breaking Earnings news story on SAGE Therapeutics »

SAGE Therapeutics reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Recommendations
Labarge analyst commentary  »

L Brands selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GE

General Electric

$30.09

-0.19 (-0.63%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Periodicals
Suez in the running for General Electric's water unit, Reuters reports »

France's Suez is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

DLHC

DLH Holdings Corp.

$5.27

-0.08 (-1.50%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Initiation
DLH Holdings Corp. initiated  »

DLH Holdings Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CM

CIBC

$89.90

0.44 (0.49%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Earnings
CIBC reports Q1 adjusted EPS C$2.89, consensus C$1.96 »

Reports Q1 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMRE

Global Medical REIT

$8.48

0.06 (0.71%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Initiation
Global Medical REIT initiated  »

Global Medical REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:25
02/23/17
02/23
06:25
02/23/17
06:25
Hot Stocks
Teleflex CEO Benson Smith retiring at end of 2017, succeeded by COO Liam Kelly »

Teleflex CEO Benson Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

MBLY

Mobileye

$47.42

1.3 (2.82%)

06:22
02/23/17
02/23
06:22
02/23/17
06:22
Recommendations
Mobileye analyst commentary  »

Mobileye price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:20
02/23/17
02/23
06:20
02/23/17
06:20
Hot Stocks
Carter's raises quarterly dividend 12% to 37c per share »

For payment on March 24…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:19
02/23/17
02/23
06:19
02/23/17
06:19
Earnings
Carter's sees FY17 adjusted EPS growth 8%-10%, consensus $5.52 »

For fiscal 2017, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:18
02/23/17
02/23
06:18
02/23/17
06:18
Earnings
Carter's sees Q1 adjusted EPS 80c-85c, consensus $1.14 »

For the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NVCR

Novocure

$7.15

-0.15 (-2.05%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Hot Stocks
Novocure Chief Commercial Officer Peter Melnyk departing »

Novocure's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 02

    Mar

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Periodicals
Credit Suisse allocates $600M to expand Saudi Arabia business, Bloomberg says »

Credit Suisse is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

OUT

OUTFRONT Media

$26.89

-0.44 (-1.61%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Downgrade
OUTFRONT Media rating change  »

OUTFRONT Media downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Breaking Hot Stocks news story on Carter's »

Carter's raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Energy Focus sees Q1 restructuring charges of $1.1M »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Earnings
Carter's reports Q4 adjusted EPS $1.79, consensus $1.67 »

Reports Q4 revenue $934M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CMVT

Comverse

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Periodicals
Former Comverse CEO faces sentencing in fraud case, Reuters reports »

Jacob "Kobi"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Recommendations
Energy Focus analyst commentary  »

Energy Focus reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BAYRY

Bayer

$113.85

-1.15 (-1.00%)

, MON

Monsanto

$111.38

0.81 (0.73%)

06:13
02/23/17
02/23
06:13
02/23/17
06:13
Periodicals
Bayer looks to raise $19B in equity to fund proposed Monsanto deal, WSJ reports »

Bayer (BAYRY) is looking…

BAYRY

Bayer

$113.85

-1.15 (-1.00%)

MON

Monsanto

$111.38

0.81 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

  • 01

    Apr

  • 26

    Jun

IRM

Iron Mountain

$37.14

-0.57 (-1.51%)

06:13
02/23/17
02/23
06:13
02/23/17
06:13
Earnings
Iron Mountain sees FY17 revenue growth 8%-10%, consensus $3.8B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 01

    Mar

  • 20

    Apr

TSLA

Tesla

$273.51

-3.88 (-1.40%)

06:12
02/23/17
02/23
06:12
02/23/17
06:12
Recommendations
Tesla analyst commentary  »

JPMorgan sees another…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRM

Iron Mountain

$37.14

-0.57 (-1.51%)

06:12
02/23/17
02/23
06:12
02/23/17
06:12
Earnings
Iron Mountain reports Q4 adjusted EPS 26c, consensus 28c »

Reports Q4 revenue $934M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 01

    Mar

  • 20

    Apr

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:11
02/23/17
02/23
06:11
02/23/17
06:11
Hot Stocks
Carter's acquires Skip Hop Holdings for $140M in cash »

Carter's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.